Pharma Horizons: Nitrosamines

The definitive guide to navigating the next phase of nitrosamine compliance. This expert report sets out the strategies that quality and manufacturing professionals need as nitrosamine management matures from basic testing towards lifecycle risk management, in a landscape of growing NDSRIs complexity, AI-assisted methods for enhanced detection and control.

As it stands, nitrosamine control is unlikely to become a mainstay in quality control in the near future. Analytical experts still require robust methodologies to determine nitrosamine formation. Mitigation strategies still need improvement to support drug formulators. Meanwhile, enhanced process control methods also need to be developed so manufacturers and packaging scientists can deliver safe, high-quality products.

As analytical capability continues to advance alongside regulatory expectations, success will increasingly depend on combining scientific understanding with effective collaboration across quality, manufacturing, analytical development and regulatory affairs.

This market report provides essential insight for pharmaceutical professionals to address the key obstacles and developments around nitrosamine prevention in 2026.

Inside this report you’ll discover:

• How nitrosamine management is evolving and how this impacts quality, manufacturing and regulatory strategies across the pharmaceutical industry
• Practical strategies for monitoring and controlling contamination of this critical impurity to overcome quality and manufacturing challenges
• As effective nitrosamine management becomes a measure of pharmaceutical manufacturing maturity, how quality professionals can benefit from understanding nitrosamine contamination as a lifecycle quality challenge and what success looks like in this area
• How leveraging AI can strengthen risk assessment and impurity control, where its limitations remain and how regulators are shaping its future use
• As NDSRIs demand grows more complex, which analytical and risk management strategies manufacturers should utilise to address the new generation of nitrosamine challenges
• The EU’s regulatory position on alternative approaches to animal testing of non-mutagenic impurities (NMIs) and what this means for regulatory compliance for pharma, particularly quality and manufacturing sectors.

Access your free nitrosamines market report and receive expert insights from European Pharmaceutical Review >>